Genitourinary Cancers

Although standard chemotherapy is often effective in the first-line treatment of locally invasive urothelial carcinoma, until recently, there have been few second- or third-line treatment options for patients with advanced or metastatic disease. Read More ›

Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial

At the 2018 Genitourinary Cancers Symposium, lead investigator Alison Jane Birtle, MD, MBBS, MRCP, FRCR, presented the results of the phase 3 POUT clinical trial, which showed that adjuvant chemotherapy had impressive gains in the disease-free survival and metastasis-free survival in upper-tract urothelial cancer

Read More ›

Androgen deprivation therapy (ADT) for the treatment of prostate cancer has adverse effects that may be difficult for men to tolerate. Read More ›

Monitoring for Bone Health
Dianna Shafer talks about the testing protocol when examining patients’ bones and what they prescribe to ensure their patients’ bone health is being addressed. Read More ›

Treatment When Cancer Metastasizes

Skeletal-Related Events for Bone Metastases
Pam Skurkay, Dianna Shafer, and Angela Hunter discuss the rates of incidences of this issue as well as the benefits of using Xgeva, including a better quality of life for patients. Read More ›

Patients with Metastatic Prostate Cancer

Technology and Bone Health Therapies
Pam Skurkay, Dianna Shafer, and Angela Hunter talk about how technology and new medicines are not only helpful for patients, but assists researchers and providers in finding more information including locating clinical trials. Read More ›

Prescribing Patterns in Low Trauma Bone Fractures

Factors Surrounding Use of Antiresportive Agents and Xgeva
Pam Skurkay talks about when providers consider prescribing one class of drugs versus another with factors that include the patient's insurance and overall health. Read More ›

Page 1 of 6


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: